Clinical Trial

Vitamin D for Prostate Endocrine Therapy

Study acronym: ViPER
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This phase III trial tests whether high-dose vitamin D works in treating androgen-deprivation therapy (ADT)-induced bone loss in patients with prostate cancer who are undergoing androgen-deprivation therapy. Vitamins are substances that the body needs to grow and develop normally. Vitamin D helps the body absorb calcium. Calcium is one of the main building blocks of bone. A lack of vitamin D can lead to bone diseases such as osteoporosis or rickets. This trial may help researchers determine if high-dose vitamin D helps keep bones strong, lowers number of falls, and lessens fatigue in men getting androgen-deprivation therapy.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2023-04-20; most recent amendment 2026-01-14.
Status change: Not Yet Recruiting → Recruiting 2024-01-16
Trial Details
NCT Number NCT05838716
Lead Sponsor University of Rochester
Collaborators: National Cancer Institute (NCI)
Conditions Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Enrollment 240 participants
Start Date 2023-12-14
Primary Completion 2029-04-29 (estimated)
Study Completion 2029-04-29 (estimated)
Updated on ClinicalTrials.gov 2026-01-15